[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported insider transactions executed on 08/20/2025. He exercised 175,000 stock options at a $2.75 exercise price, acquiring 175,000 Class A common shares. On the same date he sold 279,244 Class A common shares at a weighted average price of $9.38, with sale prices ranging from $9.30 to $9.40 per share.
After these transactions the Form 4 shows Mr. Boyer beneficially owned 431,670 Class A shares before the sale line and 152,426 Class A shares following the sale line, and held 97,480 options (derivative securities) after the reported option exercise. The filing was signed by an attorney-in-fact on 08/22/2025 and notes the exercised options were fully vested.
Andrew S. Boyer, Vicepresidente Esecutivo di Amneal Pharmaceuticals (AMRX), ha segnalato operazioni di insider eseguite il 20/08/2025. Ha esercitato 175.000 opzioni su azioni a un prezzo di esercizio di $2,75, acquisendo 175.000 azioni ordinarie di Classe A. Nello stesso giorno ha venduto 279.244 azioni ordinarie di Classe A a un prezzo medio ponderato di $9,38, con prezzi di vendita compresi tra $9,30 e $9,40 per azione.
Dopo queste operazioni il Form 4 indica che il Sig. Boyer possedeva beneficiariamente 431.670 azioni di Classe A prima della riga di vendita e 152.426 azioni di Classe A dopo la riga di vendita, e deteneva 97.480 opzioni (strumenti derivati) dopo l'esercizio delle opzioni riportato. La comunicazione 猫 stata firmata da un procuratore il 22/08/2025 e specifica che le opzioni esercitate erano completamente maturate.
Andrew S. Boyer, Vicepresidente Ejecutivo de Amneal Pharmaceuticals (AMRX), inform贸 transacciones de insiders ejecutadas el 20/08/2025. 贰箩别谤肠颈贸 175.000 opciones sobre acciones a un precio de ejercicio de $2,75, adquiriendo 175.000 acciones ordinarias Clase A. En la misma fecha vendi贸 279.244 acciones ordinarias Clase A a un precio medio ponderado de $9,38, con precios de venta entre $9,30 y $9,40 por acci贸n.
Tras estas operaciones, el Form 4 muestra que el Sr. Boyer pose铆a beneficiariamente 431.670 acciones Clase A antes de la l铆nea de venta y 152.426 acciones Clase A despu茅s de la l铆nea de venta, y manten铆a 97.480 opciones (valores derivados) despu茅s del ejercicio de opciones reportado. La presentaci贸n fue firmada por un apoderado el 22/08/2025 y se帽ala que las opciones ejercidas estaban totalmente consolidadas.
Amneal Pharmaceuticals(AMRX)鞚� 攵�靷灔(Executive Vice President) Andrew S. Boyer臧� 2025-08-20鞐� 鞁ろ枆霅� 雮措秬鞛� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 頄夓偓 臧�瓴� $2.75搿� 175,000欤� 欤检嫕毵れ垬靹犿儩甓�鞚� 頄夓偓頃橃棳 175,000欤检潣 韥措灅鞀� A 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟. 臧欖潃 雮� 攴鸽姅 279,244欤� 韥措灅鞀� A 氤错喌欤�毳� 臧�欷戫弶攴� 臧�瓴� $9.38鞐� 毵る弰頄堨溂氅�, 毵る弰 臧�瓴╈潃 欤茧嫻 $9.30鞐愳劀 $9.40 靷澊鞓�鞀惦媹雼�.
鞚� 瓯半灅 鞚错泟 Form 4鞐愲姅 Boyer 鞌皜 毵る弰 霛检澑 鞚挫爠鞐� 431,670欤� 韥措灅鞀� A毳� 鞁れ 氤挫湢頃橁碃 鞛堨棃瓿� 毵る弰 霛检澑 鞚错泟鞐愲姅 152,426欤� 韥措灅鞀� A毳� 氤挫湢頄堨溂氅�, 鞁犼碃霅� 鞓奠厴 頄夓偓 頉勳棎電� 97,480臧滌潣 鞓奠厴(韺岇儩歃濌秾)鞚� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹滊電� 2025-08-22鞐� 鞙勳瀯雽�毽澑鞚� 靹滊獏頄堨溂氅�, 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺�(vested)霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Andrew S. Boyer, vice-pr茅sident ex茅cutif d'Amneal Pharmaceuticals (AMRX), a d茅clar茅 des transactions d'initi茅s ex茅cut茅es le 20/08/2025. Il a exerc茅 175 000 options au prix d'exercice de 2,75 $, acqu茅rant 175 000 actions ordinaires de classe A. Le m锚me jour, il a vendu 279 244 actions ordinaires de classe A 脿 un prix moyen pond茅r茅 de 9,38 $, les prix de vente variant de 9,30 $ 脿 9,40 $ par action.
Apr猫s ces op茅rations, le Form 4 indique que M. Boyer poss茅dait b茅n茅ficiairement 431 670 actions de classe A avant la ligne de vente et 152 426 actions de classe A apr猫s la ligne de vente, et d茅tenait 97 480 options (titres d茅riv茅s) apr猫s l'exercice des options d茅clar茅. Le d茅p么t a 茅t茅 sign茅 par un mandataire le 22/08/2025 et pr茅cise que les options exerc茅es 茅taient enti猫rement acquises.
Andrew S. Boyer, Executive Vice President von Amneal Pharmaceuticals (AMRX), meldete Insider-Transaktionen, die am 20.08.2025 ausgef眉hrt wurden. Er 眉bte 175.000 Aktienoptionen zu einem Aus眉bungspreis von $2,75 aus und erwarb damit 175.000 Stammaktien der Klasse A. Am selben Tag verkaufte er 279.244 Stammaktien der Klasse A zu einem gewichteten Durchschnittspreis von $9,38; die Verkaufspreise lagen zwischen $9,30 und $9,40 pro Aktie.
Nach diesen Transaktionen zeigt das Form 4, dass Herr Boyer vor der Verkaufszeile 431.670 Klasse-A-Aktien wirtschaftlich besa脽 und nach der Verkaufszeile 152.426 Klasse-A-Aktien hielt, sowie nach dem gemeldeten Optionsaus眉bung 97.480 Optionen (Derivative). Die Einreichung wurde am 22.08.2025 von einem Bevollm盲chtigten unterschrieben und vermerkt, dass die ausge眉bten Optionen vollst盲ndig unverfallbar (fully vested) waren.
- Exercise of 175,000 fully vested options at a $2.75 strike, demonstrating realization of option value
- Full disclosure of sale price range (sales between $9.30 and $9.40) and weighted average price $9.38
- Significant share sale of 279,244 shares reduced reported direct beneficial ownership to 152,426 Class A shares
- Large insider liquidity event could be viewed as increased insider selling despite option exercise
Insights
TL;DR: Insider exercised a large number of vested options at a low strike and sold a larger block of shares the same day.
The filing documents a simultaneous option exercise and significant share sale by an executive. Exercising 175,000 options at a $2.75 strike realizes intrinsic value when shares trade near the reported sale prices of $9.30鈥�$9.40. The disclosed weighted average sale price is $9.38. The net effect was a reduction in reported direct beneficial ownership to 152,426 Class A shares while leaving 97,480 options recorded post-transaction. These are routine Section 16 transactions but materially large in share count and thus relevant to investors tracking insider liquidity.
TL;DR: Transaction is documented and signed by attorney-in-fact; options are fully vested per the filer.
The Form 4 includes necessary disclosures: transaction codes, prices, quantities, and a footnote clarifying the weighted-average sale price range. The filing states the exercised options are fully vested, reducing potential questions about timing relative to vesting. The signature by an attorney-in-fact is properly noted with date 08/22/2025. No amendments or additional restrictive details are provided in this filing.
Andrew S. Boyer, Vicepresidente Esecutivo di Amneal Pharmaceuticals (AMRX), ha segnalato operazioni di insider eseguite il 20/08/2025. Ha esercitato 175.000 opzioni su azioni a un prezzo di esercizio di $2,75, acquisendo 175.000 azioni ordinarie di Classe A. Nello stesso giorno ha venduto 279.244 azioni ordinarie di Classe A a un prezzo medio ponderato di $9,38, con prezzi di vendita compresi tra $9,30 e $9,40 per azione.
Dopo queste operazioni il Form 4 indica che il Sig. Boyer possedeva beneficiariamente 431.670 azioni di Classe A prima della riga di vendita e 152.426 azioni di Classe A dopo la riga di vendita, e deteneva 97.480 opzioni (strumenti derivati) dopo l'esercizio delle opzioni riportato. La comunicazione 猫 stata firmata da un procuratore il 22/08/2025 e specifica che le opzioni esercitate erano completamente maturate.
Andrew S. Boyer, Vicepresidente Ejecutivo de Amneal Pharmaceuticals (AMRX), inform贸 transacciones de insiders ejecutadas el 20/08/2025. 贰箩别谤肠颈贸 175.000 opciones sobre acciones a un precio de ejercicio de $2,75, adquiriendo 175.000 acciones ordinarias Clase A. En la misma fecha vendi贸 279.244 acciones ordinarias Clase A a un precio medio ponderado de $9,38, con precios de venta entre $9,30 y $9,40 por acci贸n.
Tras estas operaciones, el Form 4 muestra que el Sr. Boyer pose铆a beneficiariamente 431.670 acciones Clase A antes de la l铆nea de venta y 152.426 acciones Clase A despu茅s de la l铆nea de venta, y manten铆a 97.480 opciones (valores derivados) despu茅s del ejercicio de opciones reportado. La presentaci贸n fue firmada por un apoderado el 22/08/2025 y se帽ala que las opciones ejercidas estaban totalmente consolidadas.
Amneal Pharmaceuticals(AMRX)鞚� 攵�靷灔(Executive Vice President) Andrew S. Boyer臧� 2025-08-20鞐� 鞁ろ枆霅� 雮措秬鞛� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 頄夓偓 臧�瓴� $2.75搿� 175,000欤� 欤检嫕毵れ垬靹犿儩甓�鞚� 頄夓偓頃橃棳 175,000欤检潣 韥措灅鞀� A 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟. 臧欖潃 雮� 攴鸽姅 279,244欤� 韥措灅鞀� A 氤错喌欤�毳� 臧�欷戫弶攴� 臧�瓴� $9.38鞐� 毵る弰頄堨溂氅�, 毵る弰 臧�瓴╈潃 欤茧嫻 $9.30鞐愳劀 $9.40 靷澊鞓�鞀惦媹雼�.
鞚� 瓯半灅 鞚错泟 Form 4鞐愲姅 Boyer 鞌皜 毵る弰 霛检澑 鞚挫爠鞐� 431,670欤� 韥措灅鞀� A毳� 鞁れ 氤挫湢頃橁碃 鞛堨棃瓿� 毵る弰 霛检澑 鞚错泟鞐愲姅 152,426欤� 韥措灅鞀� A毳� 氤挫湢頄堨溂氅�, 鞁犼碃霅� 鞓奠厴 頄夓偓 頉勳棎電� 97,480臧滌潣 鞓奠厴(韺岇儩歃濌秾)鞚� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹滊電� 2025-08-22鞐� 鞙勳瀯雽�毽澑鞚� 靹滊獏頄堨溂氅�, 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺�(vested)霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Andrew S. Boyer, vice-pr茅sident ex茅cutif d'Amneal Pharmaceuticals (AMRX), a d茅clar茅 des transactions d'initi茅s ex茅cut茅es le 20/08/2025. Il a exerc茅 175 000 options au prix d'exercice de 2,75 $, acqu茅rant 175 000 actions ordinaires de classe A. Le m锚me jour, il a vendu 279 244 actions ordinaires de classe A 脿 un prix moyen pond茅r茅 de 9,38 $, les prix de vente variant de 9,30 $ 脿 9,40 $ par action.
Apr猫s ces op茅rations, le Form 4 indique que M. Boyer poss茅dait b茅n茅ficiairement 431 670 actions de classe A avant la ligne de vente et 152 426 actions de classe A apr猫s la ligne de vente, et d茅tenait 97 480 options (titres d茅riv茅s) apr猫s l'exercice des options d茅clar茅. Le d茅p么t a 茅t茅 sign茅 par un mandataire le 22/08/2025 et pr茅cise que les options exerc茅es 茅taient enti猫rement acquises.
Andrew S. Boyer, Executive Vice President von Amneal Pharmaceuticals (AMRX), meldete Insider-Transaktionen, die am 20.08.2025 ausgef眉hrt wurden. Er 眉bte 175.000 Aktienoptionen zu einem Aus眉bungspreis von $2,75 aus und erwarb damit 175.000 Stammaktien der Klasse A. Am selben Tag verkaufte er 279.244 Stammaktien der Klasse A zu einem gewichteten Durchschnittspreis von $9,38; die Verkaufspreise lagen zwischen $9,30 und $9,40 pro Aktie.
Nach diesen Transaktionen zeigt das Form 4, dass Herr Boyer vor der Verkaufszeile 431.670 Klasse-A-Aktien wirtschaftlich besa脽 und nach der Verkaufszeile 152.426 Klasse-A-Aktien hielt, sowie nach dem gemeldeten Optionsaus眉bung 97.480 Optionen (Derivative). Die Einreichung wurde am 22.08.2025 von einem Bevollm盲chtigten unterschrieben und vermerkt, dass die ausge眉bten Optionen vollst盲ndig unverfallbar (fully vested) waren.
FAQ
What transactions did Andrew S. Boyer report on Form 4 for AMRX?
How many shares did Mr. Boyer beneficially own after the reported transactions?
Were the exercised options vested according to the filing?
What was the price range for the share sales reported?
Who signed the Form 4 and when?
